Sign in Subscribe

article

A collection of 624 issues

PEGASUS Phase 2 Trial Tests ctDNA-Guided Adjuvant Therapy in Colon Cancer

Skip to content The CRC Digest ◆ TRIAL DATA PEGASUS Phase 2 Trial Tests ctDNA-Guided Adjuvant Therapy in Colon Cancer A Phase 2 trial is evaluating whether circulating tumor DNA can guide adjuvant treatment decisions in colon cancer patients after surgery. (Oncodaily) This content is informational only and does not constitute

What Causes Colorectal Cancer in the Young?

Skip to content The CRC Digest What Causes Colorectal Cancer in the Young? An age-specific attributable fraction analysis estimated population attributable fractions for lifestyle and medical risk factors across three age groups (30-49, 50-69, and ≥70 years), using birth-cohort-specific prevalence data from NHANES 1999-2002 and CRC incidence from Global Cancer

Impact of the Australian National Bowel Cancer Screening Program on Stage at Diagnosis and Survival

Skip to content The CRC Digest ▪ SCREENING Impact of the Australian National Bowel Cancer Screening Program on Stage at Diagnosis and Survival A retrospective cohort study of 881 colorectal cancer episodes from 2010 to 2024 examined overall survival differences between screen-detected and non-screen-detected cancers for each stage I-III; the Australian

ctDNA in the Management of Resectable & Advanced Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH ctDNA in the Management of Resectable & Advanced Colorectal Cancer A structured narrative review synthesizes evidence on circulating tumor DNA as a biomarker for molecular residual disease after curative-intent treatment, covering tumor-informed and tumor-agnostic assay strategies, postoperative sampling, and serial versus landmark testing

PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors

Skip to content The CRC Digest ◇ RESEARCH PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors Researchers identified PADI1 and PADI3 as negative prognostic markers in KRAS-mutant colorectal and pancreatic cancers; pharmacological inhibition of PADIs synergizes with KRAS inhibitors in preclinical models and restores sensitivity in resistant cells. (Cell Rep) This

Real-Time AI-Assisted Detection of Colonic Lesions Using the iIDEAS Intelligent-C Module

Skip to content The CRC Digest ▪ SCREENING Real-Time AI-Assisted Detection of Colonic Lesions Using the iIDEAS Intelligent-C Module A prospective single-center validation study (NCT05784935) tested the iIDEAS-C computer-aided detection system during colonoscopy, with co-primary endpoints of adenomas per colonoscopy and lesion-level miss rate. (JGH Open) This content is informational only

Non-Invasive Colorectal Cancer Screening Using Stool- and Blood-Based Tests

Skip to content The CRC Digest ▪ SCREENING Non-Invasive Colorectal Cancer Screening Using Stool- and Blood-Based Tests A new review synthesizes evidence on fecal immunochemical testing (FIT), multi-omics stool DNA-FIT, multi-omics stool RNA-FIT, and blood-based assays for asymptomatic individuals at average risk, emphasizing the distinction between cancer detection and advanced precancerous

Pathological complete response to pembrolizumab in dMMR CRC despite radiological residual disease

Skip to content The CRC Digest Pathological complete response to pembrolizumab in dMMR CRC despite radiological residual disease A case report describes a 70-year-old man with dMMR sigmoid colon cancer and liver metastases who achieved pathological complete response in both primary and metastatic lesions after preoperative pembrolizumab, despite imaging suggesting

Machine learning models tested for mortality prediction in Tennessee early-onset CRC patients

Skip to content The CRC Digest Machine learning models tested for mortality prediction in Tennessee early-onset CRC patients A retrospective study of 3,467 Tennessee patients aged 20–49 compared machine learning algorithms for predicting all-cause mortality and 1-, 3-, and 5-year mortality. (Cancer Epidemiol) This content is informational only

German trial to test invitation strategies for CRC screening in adults under 50

Skip to content The CRC Digest German trial to test invitation strategies for CRC screening in adults under 50 The PETER trial will assess the effect of postal and digital invitations and reminders on faecal immunochemical test use and early detection among younger adults. (BMJ Open) This content is informational